Vunakizumab
drugOn this page
Also known as Shr-1314
Summary
Vunakizumab (CHEMBL4298102) is a phase-3 clinical-stage antibody; indicated across 5 conditions including psoriasis and ankylosing spondylitis.
At a glance
- Status: Max clinical phase 3 (not approved)
- Modality: Antibody
- Indications: 5 conditions
- Clinical trials: 19
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL4298102 |
| Name | Vunakizumab |
| Type | Antibody |
| Max phase | 3 |
Also known as: Shr-1314, SHR-1314, Vunakizumab, VUNAKIZUMAB
Targets
Targets
No target linkage available.
Bioactivity
No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
5 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).
| Indication | Trial phase | MONDO | EFO |
|---|---|---|---|
| psoriasis | 3 | MONDO:0005083 | EFO:0000676 |
| ankylosing spondylitis | 2 | MONDO:0005306 | EFO:0003898 |
| lupus nephritis | 2 | MONDO:0005556 | EFO:0005761 |
| psoriatic arthritis | 2 | MONDO:0011849 | EFO:0003778 |
1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.
Clinical trials
Total trials: 19.
Phase distribution
| Phase | Trials |
|---|---|
| PHASE1 | 7 |
| PHASE3 | 4 |
| PHASE2 | 4 |
| PHASE4 | 2 |
| PHASE2/PHASE3 | 1 |
| PHASE1/PHASE2 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT06779097 | PHASE4 | NOT_YET_RECRUITING | Phase IV Study: Vunakizumab Efficacy and Safety in Moderate-to-severe Plaque Psoriasis |
| NCT07373847 | PHASE4 | NOT_YET_RECRUITING | Vunakizumab Combined With Recaticimab in Subjects With Moderate to Severe Plaque Psoriasis and Dyslipidemia |
| NCT06640257 | PHASE3 | RECRUITING | A Study of the Efficacy and Safety of SHR-1314 for Adult Active Psoriatic Arthritis |
| NCT06833307 | PHASE3 | NOT_YET_RECRUITING | The Efficacy and Safety of SHR-1314 in the Treatment of Pediatric Patients of Age 6 to <18 Years With Moderate to Severe Plaque Psoriasis |
| NCT06860750 | PHASE3 | RECRUITING | A Trial of SHR-1314 Injection in Adult Patients With Active Non-radiographic Axial Spondyloarthritis |
| NCT04839016 | PHASE3 | UNKNOWN | Efficacy 、Safety and PK of SHR-1314 in Patients With Moderate-to-Severe Plaque Psoriasis |
| NCT04840485 | PHASE2/PHASE3 | COMPLETED | Efficacy and Safety of SHR-1314 in Patients With Active Ankylosing Spondylitis |
| NCT07069270 | PHASE2 | NOT_YET_RECRUITING | A Study on the First-line Treatment of Small Cell Lung Cancer With Adebrelimab and Vunakizumab and Chemotherapy |
| NCT03463187 | PHASE1/PHASE2 | COMPLETED | Multi-Dose Study of SHR-1314 in Subjects With Moderate-to-severe Plaque Psoriasis |
| NCT04924296 | PHASE2 | UNKNOWN | A Phase II Study to Evaluate the Efficacy and Safety of SHR-1314 in Lupus Nephritis |
| NCT05055934 | PHASE2 | COMPLETED | Study of the Effectiveness and Safety of SHR-1314 for Psoriatic Arthritis |
| NCT05394857 | PHASE2 | TERMINATED | Efficacy and Safety of SHR-1314 by Subcutaneous Injection in Active Moderate to Severe Graves’ Orbitopathy Patients |
| NCT06881290 | PHASE1 | RECRUITING | Vunakizumab for the Treatment of Mild to Moderate Systemic Lupus Erythematosus |
| NCT02934412 | PHASE1 | COMPLETED | A Study of SHR-1314 in Healthy Subjects |
| NCT03704428 | PHASE1 | COMPLETED | Safety, Tolerability and PK of SHR1314 in axSpA |
| NCT03710681 | PHASE1 | UNKNOWN | A Safety Study of Multiple Subcutaneous (s.c.) Injections of SHR-1314 in Adults With Moderate-to-severe Plaque Psoriasis |
| NCT04326881 | PHASE1 | UNKNOWN | A Study to Compare Pharmacokinetic and Safety Profiles of Different Formulations of SHR-1314 After Subcutaneous Injection in Healthy Subjects |
| NCT04527484 | PHASE1 | UNKNOWN | A Bioequivalence Study to Compare Two Formulations of SHR-1314 After Subcutaneous Injection in Healthy Subjects |
| NCT06182384 | PHASE1 | COMPLETED | A Clinical Study to Compare the Safety and Pharmacokinetics of SHR-1314 Injection in Healthy Subjects at Different Specifications Devices |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).
Related Atlas pages
- Diseases: psoriasis